Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$45.54 USD
-0.15 (-0.33%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $45.58 +0.04 (0.09%) 5:48 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Company Summary
Cambridge, MA-based Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.
Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in adult patients with pyruvate kinase (PK) deficiency in the United States and the EU in 2022. Pyrukynd is also being evaluated in late-stage clinical studies for treating PK deficiency in pediatric patients. The company is also developing mitapivat for sickle cell disease (“SCD”) and thalassemia.
Agios is evaluating tebapivat (formerly, AG-946), ...
Company Summary
Cambridge, MA-based Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.
Pyrukynd (mitapivat) was approved for the treatment of hemolytic anemia in adult patients with pyruvate kinase (PK) deficiency in the United States and the EU in 2022. Pyrukynd is also being evaluated in late-stage clinical studies for treating PK deficiency in pediatric patients. The company is also developing mitapivat for sickle cell disease (“SCD”) and thalassemia.
Agios is evaluating tebapivat (formerly, AG-946), its PKR activator candidate, as a potential treatment for myelodysplastic syndrome (MDS) and hemolytic anemia in separate clinical studies. The company also advanced its investigational PAH stabilizer into clinical studies in first-half 2024.
In March 2021, Agios sold its commercial, clinical and research-stage oncology portfolio, including its wholly owned relapsed/refractory acute myeloid leukemia drug Tibsovo, to Servier for up to $2 billion.
Agios developed another product, Idhifa, in collaboration with Celgene Corporation, a wholly-owned subsidiary of Bristol-Myers Squibb Company. In June 2020, Agios divested its tiered, sales-based royalty rights on worldwide net sales of Idhifa, along with rights to receive up to $55 million in outstanding regulatory milestone payments from Bristol Myers to Royalty Pharma for $255 million.
Agios generated revenues of $26.8 million in 2023, up 88% year over year.
General Information
Agios Pharmaceuticals, Inc
88 SIDNEY STREET
CAMBRIDGE, MA 02139
Phone: 617-649-8600
Fax: NA
Web: http://www.agios.com
Email: ir@agios.com
Industry | Medical - Products |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.05 |
Current Year EPS Consensus Estimate | -4.85 |
Estimated Long-Term EPS Growth Rate | 12.00 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 45.69 |
52 Week High | 50.35 |
52 Week Low | 19.80 |
Beta | 0.75 |
20 Day Moving Average | 308,276.25 |
Target Price Consensus | 53.67 |
4 Week | 1.83 |
12 Week | 2.24 |
YTD | 105.16 |
4 Week | 1.15 |
12 Week | -0.76 |
YTD | 73.68 |
Shares Outstanding (millions) | 56.89 |
Market Capitalization (millions) | 2,599.45 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -11.92% |
vs. Previous Quarter | -16.55% |
vs. Previous Year | 28.35% |
vs. Previous Quarter | 5.20% |
Price/Book | 3.94 |
Price/Cash Flow | NA |
Price / Sales | 83.03 |
6/30/24 | -47.05 |
3/31/24 | -41.41 |
12/31/23 | -38.08 |
6/30/24 | -40.92 |
3/31/24 | -36.36 |
12/31/23 | -33.69 |
6/30/24 | 10.09 |
3/31/24 | 12.84 |
12/31/23 | 12.27 |
6/30/24 | 9.71 |
3/31/24 | 12.39 |
12/31/23 | 11.99 |
6/30/24 | -1,165.69 |
3/31/24 | -1,199.26 |
12/31/23 | -1,312.64 |
6/30/24 | -1,165.69 |
3/31/24 | -1,199.26 |
12/31/23 | -1,312.64 |
6/30/24 | -1,165.69 |
3/31/24 | -1,199.26 |
12/31/23 | -1,312.64 |
6/30/24 | 11.61 |
3/31/24 | 13.10 |
12/31/23 | 14.51 |
6/30/24 | 0.16 |
3/31/24 | 0.16 |
12/31/23 | 0.18 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |